Fig. 6

Hypothetical carboplatin doses were re-evaluated within the clinical context.The patients who received a clinically reduced carboplatin dose would have received a lower dose upfront if CKD-EPI ²⁰⁰⁹ or CKD-EPI ²⁰²¹ was used instead of CG in eGFR calculation. A The number of patients whose carboplatin dose was reduced from the original calculated dose based on their clinical presentation (e.g., ECOG performance status, observations, and subjective medical officer assessment). B and C The patients who received a clinically-reduced carboplatin dose were compared to those without dose adjustment in terms of their hypothetical carboplatin dose change as a result of substituting CG with CKD-EPI ²⁰⁰⁹ (B) or CKD-EPI ²⁰²¹(C). Data acquired from the 1^st cycle of carboplatin treatment